<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041324</url>
  </required_header>
  <id_info>
    <org_study_id>SB-913-1602</org_study_id>
    <nct_id>NCT03041324</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II</brief_title>
  <official_title>A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and
      plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. SB-913 is an
      intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts
      a correct copy of the IDS gene into the Albumin locus in hepatocytes with the goal of
      lifelong therapeutic production of the IDS enzyme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to provide long term expression of IDS and improve the
      current clinical outcome of enzyme replacement therapy (ERT) in subjects with MPS II, a
      recessive lysosomal storage disorder that results from mutations in the gene encoding IDS.
      SB-913 is a therapeutic for ZFN-mediated genome editing which will be delivered by
      adeno-associated virus (AAV)-derived vectors. SB-913 is intended to function by placement of
      the corrective copy of IDS transgene into the genome of the subject's own hepatocytes, under
      the control of the highly expressed endogenous albumin locus, and is expected to provide
      permanent, liver-specific expression of Iduronate 2-Sulfatase for the lifetime of an MPS II
      patient.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive SB-913 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-913 on IDS activity</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Change from baseline in clinical laboratory measurement of IDS activity measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-913 on urine glycosaminoglycans (GAG) levels</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Change from baseline in total GAG, DS GAG, and HS GAG (/creatinine ratio) measured in tissues including blood, liver and cerebrospinal fluid (CSF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized frequency of idursulfase (or equivalent ERT) administration.</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Change from baseline in annualized frequency of idursulfase (or equivalent ERT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAV2/6 clearance in plasma, saliva, urine, stool, and semen</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>AAV2/6 clearance by measuring vector genomes in plasma, saliva, urine, stool, and semen by PCR.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>MPS II</condition>
  <arm_group>
    <arm_group_label>Experimental: Cohort 1: SB-913: Starting Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 2: SB-913 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 3: SB-913 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 4: SB-913 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-913</intervention_name>
    <description>Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor</description>
    <arm_group_label>Experimental: Cohort 1: SB-913: Starting Dose</arm_group_label>
    <arm_group_label>Experimental: Cohort 2: SB-913 at Next Ascending Dose</arm_group_label>
    <arm_group_label>Experimental: Cohort 3: SB-913 at Next Ascending Dose</arm_group_label>
    <arm_group_label>Experimental: Cohort 4: SB-913 at Next Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 5 years of age

          -  Clinical diagnosis of MPS II (based on evidence of hepatosplenomegaly, dysostosis
             multiplex by X-ray, valvular heart disease, or obstructive airway disease) IDS
             deficiency confirmed by gene sequencing.

        Exclusion Criteria:

          -  Known to be unresponsive to ERT

          -  Neutralizing antibodies to AAV 2/6

          -  Serious intercurrent illness or clinically significant organic disease (unless
             secondary to MPS II)

          -  Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or
             hepatitis C or HIV 1/2

          -  Lack of tolerance to idursulfase treatment with significant IARs or occurrence of
             anaphylaxis

          -  Markers of hepatic dysfunction

          -  Creatinine ≥ 1.5 mg/dL

          -  Contraindication to the use of corticosteroids for immunosuppression

          -  Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use
             (topical treatment allowed)

          -  Participation in prior investigational drug or medical device study within the
             previous 3 months

          -  Prior treatment with a gene therapy product

          -  Elevated or abnormal circulating α-fetoprotein (AFP)

          -  Weight &lt; 20 kg at Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine, Neurogenetics Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS ll</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Hunter syndrome</keyword>
  <keyword>Gene Editing</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Zinc Finger</keyword>
  <keyword>ZFN</keyword>
  <keyword>SB-913</keyword>
  <keyword>Rare</keyword>
  <keyword>Genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>Genome editing</keyword>
  <keyword>Champions</keyword>
  <keyword>Hunter</keyword>
  <keyword>Gene Specific Targeted Insertion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

